


<b>Name of Sponsor:</b> IRCCS OSPEDALE SAN RAFFAELE - Prof. Andrés J. M. Ferreri		<b>Statement on discontinuation of the study</b>	 <b>I.R.C.C.S. Ospedale San Raffaele</b> Gruppo San Donato
<b>Investigational Product:</b> Romiplostin		<b>EudraCT No.:</b> 2011-003824-12	
		<b>Page:</b> 1	
<b>Report Date:</b> 07-MAY-2025	<b>Trial No. / Doc. No.:</b> ProRom - Version 2 – 12/DIC/2011		
<b>Title of Trial:</b>	Pilot phase II trial on safety and activity of secondary prophylaxis with romiplostim in patients with non-Hodgkin lymphoma and chemotherapy-induced thrombocytopenia.		
<b>Trial Sites:</b>	NA		
<b>Publications:</b>	NA		
<b>Clinical Phase:</b>	II		
<b>Statement on discontinuation of the study:</b>	It was initially planned to enroll 20 patients in 24 months, while a total of 2 patients were enrolled in 30 months. Enrollment took longer than expected due to a decrease in the observed caseload. No patients were receiving treatment at the time of study termination. Data were not enough to perform an analysis.		